... CHARLOTTESVILLE Virginia June 23 /- Biovista Inc. t... We are pleased with these initial results that confirm the predic... For a non-confidential information pack on BVA-601 contact Biovis... About Biovista's BVA-601 trial in the Kainic acid model of epileps...

"We are pleased with these initial results that confirm the predicted
efficacy of BVA-601 and encourage us to further test and develop this
compound in a disease area where there is a need for new, patient-friendly
therapies," said Aris Persidis, Ph.D., President of Biovista. "This
successful repositioning builds on our previously reported success with
BVA-101 in multiple sclerosis, expanding our CNS portfolio. At the present
time we are exploring all options available to us, including the further
co-development with a pharmaceutical company and the licensing of the IP to a
generics company," added Dr. Persidis.

For a non-confidential information pack on BVA-601, contact Biovista at
info@biovista.com.

About Biovista's BVA-601 trial in the Kainic acid model of epilepsy

Epilepsy is a common chronic neurological disorder characterized by
recurrent unprovoked seizures. These seizures may be transient signs and/or
symptoms due to abnormal, excessive or synchronous neuronal activity in the
brain. Epilepsy is one of the world's oldest recognized conditions, affecting
around 50 million people worldwide. Fear, discrimination and social stigma
have surrounded epilepsy for centuries. Some of the stigma continues today in
many countries impacting the quality of life of people with the disorder.

In the animal proof of concept trial, BVA-601 was compared to diazepam, a
potent anti-epileptic drug that is efficient in reducing epileptic activity
but has troubling adverse events. BVA-601 induced a statistically significant
reduction in the number of animals showing epileptic activity and delayed the
onset of epileptic seizures.

About Biovista's repositioning pipeline and technology platform

Biovista applies high-efficiency discovery efforts to finding solutions
for commercially relevant unmet medical needs. Biovista's proprietary
repositioning technology allows it to perform mechanism-of-action based
analyses and systematically assess clinical outcomes in any therapeutic area
of interest, at relatively low cost and short time spans. The company is
presently using this platform to develop its own pipeline of repositioned
drugs in areas such as CNS, cardiovascular disease, oncology and autoimmune
diseases.

(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer ... that they have entered into a multiyear collaboration to identify and characterize novel ... additional tools for gene editing across all applications. , Under the terms of ...

(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...

(Date:6/14/2017)... , June 15, 2017 IBM (NYSE: IBM ) ... international tech event dedicated to developing collaboration between startups and ... on June 15-17. During the event, nine startups will showcase ... value in various industries. France ... the international market, with a 30 percent increase in the ...

(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...

(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...